Aggressive lymphomas, N Engl J Med, vol.362, issue.15, pp.1417-1446, 2010. ,
Diagnosis and treatment of diffuse large B-cell lymphoma, Swiss Medical Weekly, vol.142, p.0, 2012. ,
DOI : 10.4414/smw.2012.13511
WHO Classification: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues, 2008. ,
Diffuse Aggressive B-cell Lymphomas, Advances in Anatomic Pathology, vol.16, issue.4, pp.216-251, 2009. ,
DOI : 10.1097/PAP.0b013e3181a9d5d2
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy, Blood, vol.114, issue.17, pp.3533-3540, 2009. ,
DOI : 10.1182/blood-2009-05-220095
Positron Emission Tomography for Detection and Staging of Malignant Lymphoma, Recent Results Cancer Res, vol.156, pp.78-89, 2000. ,
DOI : 10.1007/978-3-642-57054-4_10
The role of FDG-PET scans in patients with lymphoma, Blood, vol.110, issue.10, pp.3507-3523, 2007. ,
DOI : 10.1182/blood-2007-06-097238
Report of the Committee on Hodgkin's Disease Staging Classification, Cancer Res, vol.31, issue.11, pp.1860-1861, 1971. ,
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting., Journal of Clinical Oncology, vol.7, issue.11, pp.1630-1636, 1989. ,
DOI : 10.1200/JCO.1989.7.11.1630
Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B., Journal of Clinical Oncology, vol.9, issue.2, pp.220-226, 1991. ,
DOI : 10.1200/JCO.1991.9.2.220
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs., Journal of Clinical Oncology, vol.9, issue.2, pp.211-220, 1991. ,
DOI : 10.1200/JCO.1991.9.2.211
Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996, Annals of Hematology, vol.78, issue.7, pp.315-324, 1993. ,
DOI : 10.1007/s002770050521
Toxicity and response criteria of the Eastern Cooperative Oncology Group, AMERICAN JOURNAL OF CLINICAL ONCOLOGY, vol.5, issue.6, pp.649-55, 1982. ,
DOI : 10.1097/00000421-198212000-00014
Performance status is the single most important prognostic factor in lymphoma patients aged greater than 75 overriding other prognostic factors such as histology, Leukemia & Lymphoma, vol.4, issue.1 ,
DOI : 10.1093/annonc/mdl034
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte, Journal of Clinical Oncology, vol.23, issue.18, pp.4117-4143, 2005. ,
DOI : 10.1200/JCO.2005.09.131
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive ,
ACVBP versus CHOP plus Radiotherapy for Localized Aggressive Lymphoma, New England Journal of Medicine, vol.352, issue.12, pp.1197-205, 2005. ,
DOI : 10.1056/NEJMoa042040
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial, The Lancet, vol.378, issue.9806, pp.1858-67, 2011. ,
DOI : 10.1016/S0140-6736(11)61040-4
R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group, Annals of Oncology, vol.23, issue.1, pp.147-53, 2012. ,
DOI : 10.1093/annonc/mdr058
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy, Blood, vol.99, issue.8, pp.2685-93, 2002. ,
DOI : 10.1182/blood.V99.8.2685
Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients ,
The role of radiotherapy to bulky disease in the rituximab era: results from two prospective trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL) for elderly patients with DLBCL, Blood (ASH Annual Meeting Abstracts) ,
Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome, Hematological Oncology, vol.106, issue.1, pp.38-41, 2011. ,
DOI : 10.1002/hon.953
URL : http://hdl.handle.net/11383/1718498
Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT, European Radiology, vol.20, issue.4, pp.939-988, 2007. ,
DOI : 10.1007/s00330-006-0361-8
Imaging of Bone Marrow Involvement in Lymphoma: State of the Art and Future Directions, The Scientific World JOURNAL, vol.11, pp.391-402, 2011. ,
DOI : 10.1100/tsw.2011.40
A Comparison of Whole-Body MRI and CT for the Staging of Lymphoma, American Journal of Roentgenology, vol.185, issue.3, pp.711-717, 2005. ,
DOI : 10.2214/ajr.185.3.01850711
Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: Whole-body MRI, PET/CT and bone marrow biopsy, European Journal of Radiology, vol.66, issue.2, pp.325-356, 2008. ,
DOI : 10.1016/j.ejrad.2007.06.014
FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma, J Nucl Med, vol.40, issue.9, pp.1407-1420, 1999. ,
Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma, European Journal of Nuclear Medicine and Molecular Imaging, vol.30, issue.S1, pp.65-81, 2003. ,
DOI : 10.1007/s00259-003-1164-7
Bone lymphoma: 67Ga scintigraphy and CT for prediction of outcome after treatment, J Nucl Med, vol.43, issue.10, pp.1295-303, 2002. ,
Age-Related Changes in the Metabolic Activity and Distribution of the Red Marrow as Demonstrated by 2-Deoxy-2-[F-18]fluoro-d-glucose-Positron Emission Tomography, Molecular Imaging and Biology, vol.19, issue.5, pp.300-307, 2007. ,
DOI : 10.1007/s11307-007-0100-9
A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity, Annals of Nuclear Medicine, vol.29, issue.7, pp.643-652, 2009. ,
DOI : 10.1007/s12149-009-0286-9
Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET/CT, Nuclear Medicine and Biology, vol.33, issue.8, pp.999-1004, 2006. ,
DOI : 10.1016/j.nucmedbio.2006.09.005
Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma, Annals of Hematology, vol.76, issue.6, pp.687-95, 2012. ,
DOI : 10.1007/s00277-011-1353-6
18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis, J Nucl Med, vol.46, issue.6, pp.958-63, 2005. ,
18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: A systematic review and meta-analysis, European Journal of Radiology, vol.81, issue.2, pp.303-314, 2012. ,
DOI : 10.1016/j.ejrad.2010.11.020
F-18 FDG PET for Evaluation of Bone Marrow Involvement in Non-Hodgkin Lymphoma, Clinical Nuclear Medicine, vol.36, issue.7, pp.553-562, 2011. ,
DOI : 10.1097/RLU.0b013e318217aeff
FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management, Q J Nucl Med Mol Imaging, vol.52, issue.1, pp.9-16, 2008. ,
Bone involvement in patients with lymphoma: the role of FDG-PET/CT, European Journal of Nuclear Medicine and Molecular Imaging, vol.221, issue.Suppl 1, pp.60-67, 2007. ,
DOI : 10.1007/s00259-006-0238-8
Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate, European Journal of Nuclear Medicine and Molecular Imaging, vol.24, issue.5, pp.745-50, 2009. ,
DOI : 10.1007/s00259-008-1021-9
Revised Response Criteria for Malignant Lymphoma, Journal of Clinical Oncology, vol.25, issue.5, pp.579-86, 2007. ,
DOI : 10.1200/JCO.2006.09.2403
The role of FDG-PET scans in patients with lymphoma, Blood, vol.110, issue.10, pp.3507-3523, 2007. ,
DOI : 10.1182/blood-2007-06-097238
The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement, European Journal of Haematology, vol.91, issue.6, pp.473-80, 2006. ,
DOI : 10.1016/0197-2456(96)00075-X
Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index, Blood, vol.110, issue.4, pp.1278-82, 2007. ,
DOI : 10.1182/blood-2007-01-070300
Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome, Hematological Oncology, vol.106, issue.1, pp.38-41, 2011. ,
DOI : 10.1002/hon.953
Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma, Journal of Clinical Oncology, vol.25, issue.5, pp.571-579, 2007. ,
DOI : 10.1200/JCO.2006.08.2305
Diagnostic utility of bilateral bone marrow examination, Cancer, vol.96, issue.5, pp.1522-1553, 2002. ,
DOI : 10.1002/cncr.10364
Bone involvement in patients with lymphoma: the role of FDG-PET/CT, European Journal of Nuclear Medicine and Molecular Imaging, vol.221, issue.Suppl 1, pp.60-67, 2007. ,
DOI : 10.1007/s00259-006-0238-8
Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma, Annals of Hematology, vol.76, issue.6, pp.687-95, 2012. ,
DOI : 10.1007/s00277-011-1353-6
18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: A systematic review and meta-analysis, European Journal of Radiology, vol.81, issue.2, pp.303-314, 2012. ,
DOI : 10.1016/j.ejrad.2010.11.020
F-18 FDG PET for Evaluation of Bone Marrow Involvement in Non-Hodgkin Lymphoma, Clinical Nuclear Medicine, vol.36, issue.7, pp.553-562, 2011. ,
DOI : 10.1097/RLU.0b013e318217aeff
Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin???s lymphoma: a reflection of disease infiltration or just inflammation?, European Journal of Nuclear Medicine and Molecular Imaging, vol.28, issue.65, pp.1813-1834, 2009. ,
DOI : 10.1007/s00259-009-1183-0
Bone marrow biopsy morbidity: review of 2003, Journal of Clinical Pathology, vol.58, issue.4, pp.406-414, 2005. ,
DOI : 10.1136/jcp.2004.022178
Bilateral trephine bone marrow biopsies in Hodgkin's and ,
Value of bilateral bone marrow biopsy specimens in ,
Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: Whole-body MRI, PET/CT and bone marrow biopsy, European Journal of Radiology, vol.66, issue.2, pp.325-356, 2008. ,
DOI : 10.1016/j.ejrad.2007.06.014
Bilateral Trephine Bone Marrow Biopsies in Lymphoma and Other Neoplastic Diseases, Annals of Internal Medicine, vol.82, issue.3, pp.365-371, 1975. ,
DOI : 10.7326/0003-4819-82-3-365
Utility of FDG-PET scanning in lymphoma by WHO classification, Blood, vol.101, issue.10, pp.3875-3881, 2003. ,
DOI : 10.1182/blood-2002-09-2778
Detection of lymphoma in bone marrow by whole-body positron emission tomography, Blood, vol.91, issue.9, pp.3340-3346, 1998. ,
Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma?, Nuclear Medicine Communications, vol.27, issue.1, pp.11-16, 2006. ,
DOI : 10.1097/01.mnm.0000185000.81203.49
FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management, Q J Nucl Med Mol Imaging, vol.52, issue.1, pp.9-16, 2008. ,
Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients, European Journal of Nuclear Medicine and Molecular Imaging, vol.37, issue.8, pp.1469-76, 2011. ,
DOI : 10.1007/s00259-011-1815-z
A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity, Annals of Nuclear Medicine, vol.29, issue.7, pp.643-652, 2009. ,
DOI : 10.1007/s12149-009-0286-9
Correlaci??n de los par??metros hematol??gicos con la captaci??n de FDG en m??dula ??sea y bazo en la PET, Revista Espa??ola de Medicina Nuclear, vol.24, issue.2, pp.107-119, 2005. ,
DOI : 10.1157/13071686
Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET/CT, Nuclear Medicine and Biology, vol.33, issue.8, pp.999-1004, 2006. ,
DOI : 10.1016/j.nucmedbio.2006.09.005
Hematopoietic Cytokine-Mediated FDG Uptake Simulates the Appearance of Diffuse Metastatic Disease on Whole-Body PET Imaging, CLINICAL NUCLEAR MEDICINE, vol.23, issue.2, pp.93-101, 1998. ,
DOI : 10.1097/00003072-199802000-00007
Diffuse Bone Marrow Uptake on Whole-Body F-18 Fluorodeoxyglucose Positron Emission Tomography in a Patient Taking Recombinant Erythropoietin, Clinical Nuclear Medicine, vol.29, issue.3, pp.161-164, 2004. ,
DOI : 10.1097/01.rlu.0000115654.90324.02
Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate, European Journal of Nuclear Medicine and Molecular Imaging, vol.24, issue.5, pp.745-50, 2009. ,
DOI : 10.1007/s00259-008-1021-9
A Comparison of Whole-Body MRI and CT for the Staging of Lymphoma, American Journal of Roentgenology, vol.185, issue.3, pp.711-717, 2005. ,
DOI : 10.2214/ajr.185.3.01850711
Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma, European Radiology, vol.49, issue.Spec No A, pp.2027-2065, 2010. ,
DOI : 10.1007/s00330-010-1758-y